Karolina E Zaborska1, Bethany P Cummings2. 1. Department of Biomedical Sciences, Cornell University, T3 014A Veterinary Research Tower, Ithaca, NY, 14853, USA. 2. Department of Biomedical Sciences, Cornell University, T3 014A Veterinary Research Tower, Ithaca, NY, 14853, USA. bpc68@cornell.edu.
Abstract
PURPOSE OF REVIEW: Herein, we review the role of FXR and TGR5 in the regulation of hepatic bile acid metabolism, with a focus on how our understanding of bile acid metabolic regulation by these receptors has evolved in recent years and how this improved understanding may facilitate targeting bile acids for type 2 diabetes treatment. RECENT FINDINGS: Bile acid profile is a key regulator of metabolic homeostasis. Inhibition of expression of the enzyme that is required for cholic acid synthesis and thus determines bile acid profile, Cyp8b1, may be an effective target for type 2 diabetes treatment. FXR and, more recently, TGR5 have been shown to regulate bile acid metabolism and Cyp8b1 expression and, therefore, may provide a mechanism with which to target bile acid profile for type 2 diabetes treatment. Inhibition of Cyp8b1 expression is a promising therapeutic modality for type 2 diabetes; however, further work is needed to fully understand the pathways regulating Cyp8b1 expression.
PURPOSE OF REVIEW: Herein, we review the role of FXR and TGR5 in the regulation of hepatic bile acid metabolism, with a focus on how our understanding of bile acid metabolic regulation by these receptors has evolved in recent years and how this improved understanding may facilitate targeting bile acids for type 2 diabetes treatment. RECENT FINDINGS:Bile acid profile is a key regulator of metabolic homeostasis. Inhibition of expression of the enzyme that is required for cholic acid synthesis and thus determines bile acid profile, Cyp8b1, may be an effective target for type 2 diabetes treatment. FXR and, more recently, TGR5 have been shown to regulate bile acid metabolism and Cyp8b1 expression and, therefore, may provide a mechanism with which to target bile acid profile for type 2 diabetes treatment. Inhibition of Cyp8b1 expression is a promising therapeutic modality for type 2 diabetes; however, further work is needed to fully understand the pathways regulating Cyp8b1 expression.
Authors: L Galarneau; J F Paré; D Allard; D Hamel; L Levesque; J D Tugwood; S Green; L Bélanger Journal: Mol Cell Biol Date: 1996-07 Impact factor: 4.272
Authors: Hollie I Swanson; Taira Wada; Wen Xie; Barbara Renga; Angela Zampella; Eleonora Distrutti; Stefano Fiorucci; Bo Kong; Ann M Thomas; Grace L Guo; Ramesh Narayanan; Muralimohan Yepuru; James T Dalton; John Y L Chiang Journal: Drug Metab Dispos Date: 2012-10-04 Impact factor: 3.922
Authors: Su Jin Chung; Chung Hun Lee; Ho Sung Lee; Sung Tae Kim; Uy Dong Sohn; Eon Sub Park; Joon Seok Bang; Jong Hyuk Lee; Yoon Hee Chung; Ji Hoon Jeong Journal: Life Sci Date: 2014-05-29 Impact factor: 5.037
Authors: Ava Parséus; Nina Sommer; Felix Sommer; Robert Caesar; Antonio Molinaro; Marcus Ståhlman; Thomas U Greiner; Rosie Perkins; Fredrik Bäckhed Journal: Gut Date: 2016-01-06 Impact factor: 23.059